Soleno Therapeutics, Inc. announced a $100 million share repurchase and an Accelerated Share Repurchase Agreement with Jefferies LLC to buy back common stock. CEO Dr. Anish Bhatnagar expressed confidence in VYKAT XR for Prader Willi syndrome. The initial payment of $100 million will result in approximately 1,511,553 shares repurchased. The final number of shares will be based on the average stock price during the transaction. The ASR is expected to be completed in the first quarter of 2026. Soleno focuses on developing therapeutics for rare diseases, with VYKAT XR as their first commercial product. Contact Brian Ritchie for more information.

Read more at GlobeNewswire: Soleno Therapeutics Announces Entry Into $100 Million